Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer's disease, Huntington disease and other major age-related degenerative disorders. The Company's lead drug candidate, PBT2 is being developed for the treatment of Alzheimer�s and Huntington's diseases. Prana Biotechnology is developing therapies to treat neurodegenerative disease. Prana Biotechnology also has advanced a drug candidate for Parkinson�s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. The Company's activities are predominantly within Australia and cover research into Alzheimer's disease and other major age-related degenerative disorders.